Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Daptomycin.

Kerry L Tedesco1, Michael J Rybak

  • 1Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, School of Medicine, Wayne State University, Detroit, MI 48201, USA.

Pharmacotherapy
|January 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of colistin minimum inhibitory concentration on clinical failure and mortality: insights from the OVERCOME trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Beyond traditional tetracyclines: a real-world evaluation of effectiveness and safety of omadacycline therapy for complex bacterial infections.

BMC infectious diseases·2026
Same author

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers.

Antimicrobial agents and chemotherapy·2026
Same author

Real-world use of eravacycline for the treatment of mono- and polymicrobial infections involving Enterobacterales.

Microbiology spectrum·2026
Same author

Optimizing discharge antibiotic prescribing: A multicenter evaluation of pharmacist-led interventions in community hospitals.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis.

BMC infectious diseases·2025
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Daptomycin is a novel lipopeptide antibiotic effective against resistant gram-positive bacteria by disrupting their cell membranes. Its unique mechanism and safety profile make it a valuable addition to treating challenging infections.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Daptomycin is a novel lipopeptide antimicrobial agent.
  • It targets gram-positive bacterial infections, including multidrug-resistant strains.
  • Its unique mechanism of action involves disrupting the bacterial plasma membrane.

Purpose of the Study:

  • To review the characteristics and clinical utility of daptomycin.
  • To highlight its efficacy against resistant gram-positive pathogens.
  • To discuss its safety profile and place in therapy.

Main Methods:

  • Literature review of daptomycin's mechanism of action.
  • Analysis of clinical data regarding efficacy and safety.
  • Evaluation of its activity against resistant bacteria like MRSA and VRE.

Related Experiment Videos

Main Results:

  • Daptomycin exhibits concentration-dependent killing.
  • It is effective against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
  • The agent has a safety profile comparable to existing treatments for gram-positive infections.

Conclusions:

  • Daptomycin is a significant advancement in treating resistant gram-positive bacterial infections.
  • Its distinct mechanism and efficacy support its role in the antimicrobial armamentarium.
  • Further clinical experience will refine its therapeutic applications.